Liquid biopsies personalize early-stage colon cancer treatment
https://www.facingourrisk.org/XRAY/liquid-biopsy-for-early-colon-cancer
Full article: https://www.nejm.org/doi/10.1056/NEJMoa2200075?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Liquid biopsies look for DNA or other products from cancer cells in the blood or other body fluids. These tests may be used to help find cancer recurrence early, monitor response to treatment or guide treatment selection for people diagnosed with cancer. This study looked at a type of liquid biopsy called “circulating tumor” (ctDNA) to identify people with early-stage colon cancer who can safely skip chemotherapy after surgery. (Posted 11/22/22) Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- Given my stage of colorectal cancer, what are my chances of recurrence?
- Would liquid biopsy be useful for determining my need for chemotherapy and my chance of recurrence? Will my insurance pay for the test?
- What are the risks and benefits of liquid biopsy?
Open Clinical Trials
The following research studies are looking at liquid biopsy and cancer.
- NCT04962529 Breast cancer liquid biopsy trial. This study is looking at whether a liquid biopsy test in development is a less invasive alternative to a tissue biopsy in patients with suspected metastatic breast cancer.
- NCT04567420: DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer. This study will monitor people with early-stage, high-risk breast cancer for possible recurrence using a test called circulating tumor DNA (ctDNA). People who test positive for ctDNA but who have no other signs of recurrence, will receive either the drugs palbociclib combined with fulvestrant or standard-of-care adjuvant hormone therapy.
- NCT03568630 Blood markers of early pancreas cancer. This study is looking for markers of early pancreatic cancer for screening individuals who are at higher-than-average risk.
- Validating a blood test for early ovarian cancer detection in high-risk women and families: microRNA detection study (MiDE). The MiDe study is looking at whether a liquid biopsy can accurately detect early-stage ovarian cancer in women who are at high risk due to an inherited mutation.
Visit our Featured Research Page and Research Search and Enroll Tool to find additional studies enrolling people with, or at high risk for cancer.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.